| Autor: |
Kraut EH; Ohio State University Health Center, Columbus., Fleming T, Segal M, Neidhart JA, Behrens BC, MacDonald J |
| Jazyk: |
angličtina |
| Zdroj: |
Investigational new drugs [Invest New Drugs] 1991 Feb; Vol. 9 (1), pp. 95-6. |
| DOI: |
10.1007/BF00194556 |
| Abstrakt: |
Twenty-three patients with advanced pancreatic adenocarcinoma were treated with Pibenzimol utilizing a daily intravenous schedule for five days. There were no objective responses seen. The major toxicity was pancreatic with grade 3 hyperglycemia in eleven patients. Pibenzimol is inactive in patients with advanced pancreatic adenocarcinoma. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full text from SpringerLink